

## ENTYVIO REFERRAL FORM ( PAGE 1 OF 2 )

CALL: 844-800-5377 FAX: 800-239-0363 www.evolutionaryrx.com

Patient Name:		
	City State Zip	
Home Phone: Call/Work Phone:	State 21p Birth Date: / /	
Email:		
Primary Insurance (PI) Name:	PI Phone:	
Commercial  Medicare/Medicaid  Pending Medicaid	No Insurance PI Subscriber ID:	
	irth Date: / / Policy/Group ID #:	
Secondary Insurance (PI) Name:	SI Phone:	
Commercial Medicare/Medicaid Pending Medicaid	No Insurance SI Subscriber ID:	
Commercial a Medicale/Medicald a Fernanty Medicald	NO INSURANCE SI SUBSCIIDEI ID.	
HEALTHCARE PROVIDER INFORMATION		
Healthcare Provider Name:	Clinic Name (if applicable):	
Address	Clinic Name (if applicable): State Zip	
Contact Name: Phone:	Fax:	
	Fax:	
Do you prefer to be the sole  point of contact?	Fax: Fax: (for additional summary of benefits)	
SITE OF ADMINISTRATION □ Same as above	(10. 222.11.01.11.01.11.11.11.11.11.11.11.11.11.	
(If fax number is provided, a copy of patient's summary of benefits will be sen	t to the cite of administration)	
Facility Name:		
Address	CityStateZip	
Phono: Eav.	Site Tax ID#: Site NPI #:	
Thore	Site lax ID# Site INI I#	
TREATMENT INFORMATION		
Patient Diagnosis: ( Checkmark ICD-10 Code)		
Ulcerative Colitis  □ K51.00 Ulcerative (chronic) pancolitis without complications □ K51.20 Ulcerative (chronic) proctitis without complications □ K51.30 Ulcerative (chronic) rectosigmoiditis without complications □ K51.50 Left-sided colitis without complications □ K51.80 Other ulcerative colitis without complications □ K51.90 Ulcerative colitis, unspecified, without complications Has patient started therapy? □ Yes □ No If yes, last treatment date: Prior biologic therapy? □ Yes □ No Please list most recent there	Crohn's Disease  □ K50.00 Crohn's disease of small intestine without complications □ K50.10 Crohn's disease of large intestine without complications □ K50.80 Crohn's disease of both small and large intestine without complication □ K50.90 Crohn's disease, unspecified, without complications	
<ul> <li>□ K51.00 Ulcerative (chronic) pancolitis without complications</li> <li>□ K51.20 Ulcerative (chronic) proctitis without complications</li> <li>□ K51.30 Ulcerative (chronic) rectosigmoiditis without complications</li> <li>□ K51.50 Left-sided colitis without complications</li> <li>□ K51.80 Other ulcerative colitis without complications</li> <li>□ K51.90 Ulcerative colitis, unspecified, without complications</li> </ul>	<ul> <li>□ K50.00 Crohn's disease of small intestine without complications</li> <li>□ K50.10 Crohn's disease of large intestine without complications</li> <li>□ K50.80 Crohn's disease of both small and large intestine without complication</li> <li>□ K50.90 Crohn's disease, unspecified, without complications</li> </ul>	
<ul> <li>□ K51.00 Ulcerative (chronic) pancolitis without complications</li> <li>□ K51.20 Ulcerative (chronic) proctitis without complications</li> <li>□ K51.30 Ulcerative (chronic) rectosigmoiditis without complications</li> <li>□ K51.50 Left-sided colitis without complications</li> <li>□ K51.80 Other ulcerative colitis without complications</li> <li>□ K51.90 Ulcerative colitis, unspecified, without complications</li> <li>Has patient started therapy? □ Yes □ No If yes, last treatment date:</li> </ul>	<ul> <li>□ K50.00 Crohn's disease of small intestine without complications</li> <li>□ K50.10 Crohn's disease of large intestine without complications</li> <li>□ K50.80 Crohn's disease of both small and large intestine without complication</li> <li>□ K50.90 Crohn's disease, unspecified, without complications</li> </ul>	
<ul> <li>K51.00 Ulcerative (chronic) pancolitis without complications</li> <li>K51.20 Ulcerative (chronic) proctitis without complications</li> <li>K51.30 Ulcerative (chronic) rectosigmoiditis without complications</li> <li>K51.50 Left-sided colitis without complications</li> <li>K51.80 Other ulcerative colitis without complications</li> <li>K51.90 Ulcerative colitis, unspecified, without complications</li> <li>Has patient started therapy? ☐ Yes ☐ No</li> <li>If yes, last treatment date:</li> </ul>	<ul> <li>□ K50.00 Crohn's disease of small intestine without complications</li> <li>□ K50.10 Crohn's disease of large intestine without complications</li> <li>□ K50.80 Crohn's disease of both small and large intestine without complication</li> <li>□ K50.90 Crohn's disease, unspecified, without complications</li> </ul>	
<ul> <li>K51.00 Ulcerative (chronic) pancolitis without complications</li> <li>K51.20 Ulcerative (chronic) proctitis without complications</li> <li>K51.30 Ulcerative (chronic) rectosigmoiditis without complications</li> <li>K51.50 Left-sided colitis without complications</li> <li>K51.80 Other ulcerative colitis without complications</li> <li>K51.90 Ulcerative colitis, unspecified, without complications</li> <li>Has patient started therapy? ☐ Yes ☐ No If yes, last treatment date:</li> <li>Prior biologic therapy? ☐ Yes ☐ No Please list most recent ther</li> </ul>	<ul> <li>□ K50.00 Crohn's disease of small intestine without complications</li> <li>□ K50.10 Crohn's disease of large intestine without complications</li> <li>□ K50.80 Crohn's disease of both small and large intestine without complication</li> <li>□ K50.90 Crohn's disease, unspecified, without complications</li> </ul>	
□ K51.00 Ulcerative (chronic) pancolitis without complications □ K51.20 Ulcerative (chronic) proctitis without complications □ K51.30 Ulcerative (chronic) rectosigmoiditis without complications □ K51.50 Left-sided colitis without complications □ K51.80 Other ulcerative colitis without complications □ K51.90 Ulcerative colitis, unspecified, without complications Has patient started therapy? □ Yes □ No If yes, last treatment date: Prior biologic therapy? □ Yes □ No Please list most recent ther	<ul> <li>□ K50.00 Crohn's disease of small intestine without complications</li> <li>□ K50.10 Crohn's disease of large intestine without complications</li> <li>□ K50.80 Crohn's disease of both small and large intestine without complication</li> <li>□ K50.90 Crohn's disease, unspecified, without complications</li> </ul>	
□ K51.00 Ulcerative (chronic) pancolitis without complications □ K51.20 Ulcerative (chronic) proctitis without complications □ K51.30 Ulcerative (chronic) rectosigmoiditis without complications □ K51.50 Left-sided colitis without complications □ K51.80 Other ulcerative colitis without complications □ K51.90 Ulcerative colitis, unspecified, without complications Has patient started therapy? □ Yes □ No If yes, last treatment date: Prior biologic therapy? □ Yes □ No Please list most recent ther  PRESCRIPTION (REQUIRED FOR SPECIALTY PHARMACY BENEFI Initiation: Entyvio 300 mg IV Dispense:	□ K50.00 Crohn's disease of small intestine without complications □ K50.10 Crohn's disease of large intestine without complications □ K50.80 Crohn's disease of both small and large intestine without complication □ K50.90 Crohn's disease, unspecified, without complications //	
□ K51.00 Ulcerative (chronic) pancolitis without complications □ K51.20 Ulcerative (chronic) proctitis without complications □ K51.30 Ulcerative (chronic) rectosigmoiditis without complications □ K51.50 Left-sided colitis without complications □ K51.80 Other ulcerative colitis without complications □ K51.90 Ulcerative colitis, unspecified, without complications Has patient started therapy? □ Yes □ No If yes, last treatment date: Prior biologic therapy? □ Yes □ No Please list most recent ther  PRESCRIPTION (REQUIRED FOR SPECIALTY PHARMACY BENEFI Initiation: Entyvio 300 mg IV	□ K50.00 Crohn's disease of small intestine without complications □ K50.10 Crohn's disease of large intestine without complications □ K50.80 Crohn's disease of both small and large intestine without complication □ K50.90 Crohn's disease, unspecified, without complications  □ J/ □ py and date/duration: □ Continuing: Entyvio 300 mg IV	
□ K51.00 Ulcerative (chronic) pancolitis without complications □ K51.20 Ulcerative (chronic) proctitis without complications □ K51.30 Ulcerative (chronic) rectosigmoiditis without complications □ K51.50 Left-sided colitis without complications □ K51.80 Other ulcerative colitis without complications □ K51.90 Ulcerative colitis, unspecified, without complications Has patient started therapy? □ Yes □ No If yes, last treatment date: Prior biologic therapy? □ Yes □ No Please list most recent there  PRESCRIPTION (REQUIRED FOR SPECIALTY PHARMACY BENEFI Initiation: Entyvio 300 mg IV  Dispense: □ Qty: vial(s) Refill times  Dosage and Directions for Use: □ 300 mg IV infusion at Week(s)	□ K50.00       Crohn's disease of small intestine without complications         □ K50.10       Crohn's disease of large intestine without complications         □ K50.80       Crohn's disease of both small and large intestine without complications         □ K50.90       Crohn's disease, unspecified, without complications         □ J	
□ K51.00 Ulcerative (chronic) pancolitis without complications □ K51.20 Ulcerative (chronic) proctitis without complications □ K51.30 Ulcerative (chronic) rectosigmoiditis without complications □ K51.50 Left-sided colitis without complications □ K51.80 Other ulcerative colitis without complications □ K51.90 Ulcerative colitis, unspecified, without complications Has patient started therapy? □ Yes □ No If yes, last treatment date: Prior biologic therapy? □ Yes □ No Please list most recent there  PRESCRIPTION (REQUIRED FOR SPECIALTY PHARMACY BENEFI Initiation: Entyvio 300 mg IV  Dispense: □ Qty: vial(s) Refill times  Dosage and Directions for Use: □ 300 mg IV infusion at Week(s)	□ K50.00       Crohn's disease of small intestine without complications         □ K50.10       Crohn's disease of large intestine without complications         □ K50.80       Crohn's disease of both small and large intestine without complications         □ K50.90       Crohn's disease, unspecified, without complications         □ J	
□ K51.00 Ulcerative (chronic) pancolitis without complications □ K51.20 Ulcerative (chronic) proctitis without complications □ K51.30 Ulcerative (chronic) rectosigmoiditis without complications □ K51.50 Left-sided colitis without complications □ K51.80 Other ulcerative colitis without complications □ K51.90 Ulcerative colitis, unspecified, without complications Has patient started therapy? □ Yes □ No If yes, last treatment date: Prior biologic therapy? □ Yes □ No Please list most recent ther  PRESCRIPTION (REQUIRED FOR SPECIALTY PHARMACY BENEFI Initiation: Entyvio 300 mg IV Dispense: □ Qty: vial(s) Refill times Dosage and Directions for Use:	□ K50.00 Crohn's disease of small intestine without complications   □ K50.10 Crohn's disease of large intestine without complications   □ K50.80 Crohn's disease of both small and large intestine without complication   □ K50.90 Crohn's disease, unspecified, without complications      /	
□ K51.00       Ulcerative (chronic) pancolitis without complications         □ K51.20       Ulcerative (chronic) proctitis without complications         □ K51.30       Ulcerative (chronic) rectosigmoiditis without complications         □ K51.50       Left-sided colitis without complications         □ K51.80       Other ulcerative colitis without complications         □ K51.90       Ulcerative colitis, unspecified, without complications         Has patient started therapy?       □ Yes       □ No       If yes, last treatment date:         Prior biologic therapy?       □ Yes       □ No       Please list most recent ther         PRESCRIPTION (REQUIRED FOR SPECIALTY PHARMACY BENEFI         Initiation: Entyvio 300 mg IV         Dispense:       □ Oty:       vial(s)       Refill       times         Dosage and Directions for Use:       300 mg IV infusion at Week(s)       times         Do you intend to buy & bill?       □ Yes       □ No	□ K50.00 Crohn's disease of small intestine without complications   □ K50.10 Crohn's disease of large intestine without complications   □ K50.80 Crohn's disease of both small and large intestine without complication   □ K50.90 Crohn's disease, unspecified, without complications      /	
□ K51.00       Ulcerative (chronic) pancolitis without complications         □ K51.20       Ulcerative (chronic) proctitis without complications         □ K51.30       Ulcerative (chronic) rectosigmoiditis without complications         □ K51.80       Other ulcerative colitis without complications         □ K51.90       Ulcerative colitis, unspecified, without complications         Has patient started therapy?       □ Yes       □ No       If yes, last treatment date:         Prior biologic therapy?       □ Yes       □ No       Please list most recent ther         PRESCRIPTION (REQUIRED FOR SPECIALTY PHARMACY BENEFI         Initiation: Entyvio 300 mg IV         Dispense:       □ Oty:       _ times         □ Oty:       _ vial(s)       Refill       _ times         Dosage and Directions for Use:       _ 300 mg IV infusion at Week(s)       _ times         □ Other       _ Other       _ Other       _ Other         □ PRESCRIPTION AUTHORIZATION/CERTIFICATION OF MEDICAL NECESSITY/AUTHORIZATION Authorization of the above-named patient and b) the described therapy above is medically necessary and c) you have in medically necessary and c) you have	□ K50.00 Crohn's disease of small intestine without complications   □ K50.10 Crohn's disease of large intestine without complications   □ K50.80 Crohn's disease of both small and large intestine without complication   □ K50.90 Crohn's disease, unspecified, without complications    /	



## ENTYVIO REFERRAL FORM ( PAGE 2 OF 2 )

CALL: 844-800-5377 FAX: 800-239-0363 www.evolutionaryrx.com

## PATIENT AUTHORIZATION AND CO-PAY CONSENT FORM FOR ENTYVIO CONNECT

Entyvio Connect can provide certain support to you and on your behalf during the search for Entyvio therapy reimbursement and support programs including co-pay assistance. The Entyvio Connect program is an agent of Takeda Pharmaceuticals America, Inc. In order to provide this support, Entyvio Connect will need to use your health information (called "Protected Health Information" or "PHI"), and to share it with your health plan and the pharmacy that will receive your doctor's prescription. This authorization will allow your healthcare providers, health plans, and health insurers that maintain PHI about you to disclose your PHI to Entyvio Connect so that Entyvio Connect may provide this support to you or on your behalf.

## PATIENT AUTHORIZATION AND RELEASE TO COLLECT, USE, AND DISCLOSE MEDICAL INFORMATION

By signing this Authorization, I authorize my physician, health plans and pharmacy providers to disclose my Protected Health Information, including, but not limited to, information relating to my medical condition, treatment, care management, and health insurance, as well as all information provided on this form and any prescription, to Entyvio Connect and its representatives, agents, and contractors for the following purposes: (1) to assist me in my health plan coverage for Entyvio, as well as determine my eligibility for co-pay assistance; (2) to communicate with my healthcare providers and me about my medical care; (3) to facilitate the provision of products, supplies or services by a third party including, but not limited to specialty pharmacies; and (4) to register me in any applicable product registration program required for my treatment.

By checking the box below, I also authorize Takeda Pharmaceuticals America, Inc., its affiliates, and business partners to use my personal information to provide me with information and offers related to Entyvio, the diseases and conditions it treats, and related treatment options.

I consent to receive product and disease	-state information from Takeda Pharmaceuticals Ame	erica, Inc., its affiliates, service providers, and
co-promotion partners. I consent to be contact	cted through the following means (Please check the	boxes that apply and fill in your information.
You can check more than one box.):		
□ Email:		Postal Mail, at the address
below.		
I understand that my PHI disclosed under thi	s Authorization may no longer be protected by feder	ral privacy law and may be re-disclosed by
Entyvio Connect. I understand that I may refu	se to sign this Authorization and that my treatment,	payment, enrollment or eligibility for benefits
is not conditioned on my signing this Authori	ization. I understand that I am entitled to a copy of th	his Authorization. I understand that I may
cancel this Authorization at any time by maili	ng a letter requesting such cancellation to Entyvio C	onnect, PO Box 29219, Phoenix, AZ
85038-9219, but that this cancellation will no	ot apply to any information already used or disclosed	d through this Authorization. This
Authorization will expire within five (5) years	from today's date, unless a shorter period is provide	d for by state law.
Signature:		/Date//
Address:		
Patient's Printed Name:	Phone:	OK to leave a message at this number
PLEASE FAX THE SIGNED FORM TO (80	05) 456 - 0416. FOR QUESTIONS, PLEASE CALL ENTYVIO CONNEC	CT AT 1-855-ENTYVIO (1-855-368-9846),

MONDAY TO FRIDAY, FROM 8AM TO 8PM EST (EXCEPT HOLIDAYS)